CPHI vs HROW

For growth investors, Harrow Health, Inc.

(HROW) is the stronger pick with 36. 4% revenue growth year-over-year, versus -35. 4% for China Pharma Holdings, Inc. (CPHI). Analysts rate Harrow Health, Inc. (HROW) a "Buy" — based on 10 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Harrow Health, Inc.

(HROW) delivered a total return of +378. 0%, compared to -99. 8% for China Pharma Holdings, Inc. (CPHI). Over 10 years, the gap is even starker: HROW returned +914. 3% versus CPHI's -99. 5%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), China Pharma Holdings, Inc.

(CPHI) is the lower-risk stock at 1. 18β versus Harrow Health, Inc. 's 2. 13β — meaning HROW is approximately 81% more volatile than CPHI relative to the S&P 500. On balance sheet safety, China Pharma Holdings, Inc. (CPHI) carries a lower debt/equity ratio of 46% versus 5% for Harrow Health, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Harrow Health, Inc.

(HROW) is pulling ahead at 36. 4% versus -35. 4% for China Pharma Holdings, Inc. (CPHI). On earnings-per-share growth, the picture is similar: Harrow Health, Inc. grew EPS 71. 4% year-over-year, compared to 6. 9% for China Pharma Holdings, Inc.. Over a 3-year CAGR, HROW leads at 45. 4% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Harrow Health, Inc.

(HROW) is the more profitable company, earning -1. 9% net margin versus -104. 6% for China Pharma Holdings, Inc. — meaning it keeps -1. 9% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: HROW leads at 11. 2% versus -101. 3% for CPHI. At the gross margin level — before operating expenses — HROW leads at 75. 1%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, China Pharma Holdings, Inc.

(CPHI) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 18)). Harrow Health, Inc. (HROW) carries a higher beta of 2. 13 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (CPHI: -99. 5%, HROW: +914. 3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: CPHI is a small-cap quality compounder stock; HROW is a small-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.